Advanced in Mevalonate Kinase Deficiency

Michel P. Moutschen

Liege, WAL, BE 
Advanced in Mevalonate Kinase Deficiency
Liege, WAL, BE 
OverviewLocationsClinical Research

Overview

Michel Moutschen practices in Liege, Belgium. Mr. Moutschen is rated as an Advanced expert by MediFind in the treatment of Mevalonate Kinase Deficiency. His top areas of expertise are HIV/AIDS, COVID-19, Severe Acute Respiratory Syndrome (SARS), and Mevalonate Kinase Deficiency.

His clinical research consists of co-authoring 147 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Mevalonate Kinase Deficiency.

Gender
Male

Locations

Liege, WAL, Belgium
Other Locations
Mons, WAL, Belgium
Arlon, WAL, Belgium
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3

147 Total Publications

No associations between HIV reservoir and inflammation in long-term virally suppressed dolutegravir-based ART-treated individuals.
No associations between HIV reservoir and inflammation in long-term virally suppressed dolutegravir-based ART-treated individuals.
Journal: Frontiers in immunology
Published: May 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Moutschen's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile